Peptide Comparison
GHRP-6 vs Sermorelin
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Sermorelin has stronger documented evidence (Discontinued (FDA approval 1990; US withdrawal 2008)) than GHRP-6 (Anecdotal + Animal Studies) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, Sermorelin is the safer pick. GHRP-6 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| GHRP-6 | Sermorelin | |
|---|---|---|
| Class | GHRP; ghrelin receptor agonist | GHRH analog |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | GHS-R1a agonist with strong orexigenic effect | Binds GHRH receptor on pituitary somatotrophs for pulsatile GH release |
| Route | SC / Intranasal | SC injection |
| Half-life | ~15-30 min | ~10-20 min |
| Dosage (research) | 100-300 mcg SC 2-3x daily | 200-500 mcg SC at bedtime daily |
| Evidence tier | Anecdotal + Animal Studies | Discontinued (FDA approval 1990; US withdrawal 2008) |
| Research depth | 163 indexed | 149 indexed |
| Availability | Research Chemical | Compounding Restricted |
| Reported risks | Strong hunger; cortisol/prolactin rise; water retention | Injection site reactions; headache; flushing |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick GHRP-6 or Sermorelin?
Sermorelin has stronger documented evidence (Discontinued (FDA approval 1990; US withdrawal 2008)) than GHRP-6 (Anecdotal + Animal Studies) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, Sermorelin is the safer pick. GHRP-6 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between GHRP-6 and Sermorelin?
GHRP-6 is classed as GHRP; ghrelin receptor agonist; Sermorelin is classed as GHRH analog. Reported mechanism: GHRP-6, GHS-R1a agonist with strong orexigenic effect; Sermorelin, Binds GHRH receptor on pituitary somatotrophs for pulsatile GH release. Reported half-life: GHRP-6, ~15-30 min; Sermorelin, ~10-20 min. Routes in published studies: GHRP-6, SC / Intranasal; Sermorelin, SC injection.
Which has stronger evidence, GHRP-6 or Sermorelin?
GHRP-6 and Sermorelin sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. GHRP-6 is graded Anecdotal + Animal Studies, with 7 cited sources on its reference page and 163 indexed studies. Sermorelin is graded Discontinued (FDA approval 1990; US withdrawal 2008), with 6 cited sources on its reference page and 149 indexed studies.
Which is more accessible, GHRP-6 or Sermorelin?
Neither GHRP-6 nor Sermorelin is an FDA-approved drug. Catalog status: GHRP-6, Research Chemical; Sermorelin, Compounding Restricted. FDA lists GHRP-6 in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023).
Are GHRP-6 and Sermorelin ever combined?
GHRP-6 and Sermorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…